Che cosa non sappiamo sugli SGLT-2 inibitoriWhat we don’t know about SGLT-2 inhibitors

被引：0

作者：

Martina Chiriacò ^{[1
]}

Kyriazoula Chatzianagnostou ^{[2
]}

Michele Emdin ^{[2
]}

Stefano Del Prato ^{[3
]}

机构：

[1] Università di Pisa,Dipartimento di Medicina Clinica e Sperimentale

[2] Fondazione CNR Regione Toscana G. Monasterio,Centro di Ricerca Interdisciplinare “Health Science”

[3] Scuola Superiore Sant’Anna,undefined

来源：

L'Endocrinologo | 2024年 / 25卷 / 5期

关键词：

SGLT2 inibitori; Diabete tipo 2; Prediabete; Anziani; Malattia renale cronica; Malattie cardiovascolari; SGLT2 inhibitors; Type 2 diabetes; Prediabetes; Elderly; Chronic kidney disease; Cardiovascular diseases;

D O I：

10.1007/s40619-024-01510-y

中图分类号：

学科分类号：

摘要：

Gli inibitori del co-trasportatore sodio-glucosio 2 (SGLT2i) sono farmaci utilizzati per il trattamento del diabete di tipo 2 che hanno dimostrato importanti benefici cardiorenali. Nonostante l’impiego crescente di questa classe di farmaci, ci sono dati limitati riguardanti l’efficacia e la sicurezza in patologie e popolazioni specifiche come i pazienti anziani, giovani, donne in gravidanza, e la combinazione con altre terapie. Questa rassegna affronta gli ambiti di impiego degli SGLT2i attualmente poco esplorati, analizzando i dati disponibili e fornendo prospettive per ricerche future.

引用

页码：503 / 509

页数：6

共 50 条

[41] Euglycemic diabetic ketoacidosis in the era of SGLT-2 inhibitors
Chow, Erica
Clement, Stephen
Garg, Rajesh
BMJ OPEN DIABETES RESEARCH & CARE, 2023, 11 (05)
[42] SGLT-2 inhibitors: wonder drugs? Not so fast
Williams, K.
DiMarco, M.
Hebert, J.
Gibson, W. A.
Smith, D.
Coe, B. A.
Ataei, A.
Hoppens, K.
Sanne, S.
Vignes, S.
AMERICAN JOURNAL OF THE MEDICAL SCIENCES, 2024, 367 : S82 - S82
[43] SGLT-2 inhibitors for people with type 2 diabetes Reply
Zelniker, Thomas A.
Wiviott, Stephen D.
Raz, Itamar
Sabatine, Marc S.
LANCET, 2019, 394 (10198): : 560 - 561
[44] Different safety profiles for SGLT-2 vs SGLT-1/2 inhibitors for T2DM
Reactions Weekly, 2022, 1900 (1) : 7 - 7
[45] Emerging Role of SGLT-2 Inhibitors for the Treatment of Obesity
Pereira, Maria J.
Eriksson, Jan W.
DRUGS, 2019, 79 (03) : 219 - 230
[46] SGLT-2 inhibitors: pharmacokinetics characteristics and effects on lipids
Filippas-Ntekouan, Sempastian
Tsimihodimos, Vasilios
Filippatos, Theodosios
Dimitriou, Theodora
Elisaf, Moses
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2018, 14 (11) : 1113 - 1121
[47] Metformin versus SGLT-2 inhibitors: how low can we go?
Pruijm, Menno
Phan, Olivier
Zanchi, Anne
KIDNEY INTERNATIONAL, 2022, 101 (05) : 874 - 877
[48] Diabetes and kidney disease: the role of sodium-glucose cotransporter-2 (SGLT-2) and SGLT-2 inhibitors in modifying disease outcomes
Mende, Christian W.
CURRENT MEDICAL RESEARCH AND OPINION, 2017, 33 (03) : 541 - 551
[49] Guarding the heart: How SGLT-2 inhibitors protect against chemotherapy-induced cardiotoxicity SGLT-2 inhibitors and chemotherapy-induced cardiotoxicity
Vafa, Reza Golchin
Sabahizadeh, Amirreza
Mofarrah, Ramina
CURRENT PROBLEMS IN CARDIOLOGY, 2024, 49 (03)
[50] Relook at DPP-4 inhibitors in the era of SGLT-2 inhibitors
Singh, Awadhesh Kumar
Singh, Ritu
WORLD JOURNAL OF DIABETES, 2022, 13 (06) : 466 - 470

← 1 2 3 4 5 →